releases: https://craig.house.gov/media/press-releases/representative-angie-craig-colleagues-urge-leader-schumer-bring-forward-stand
Data license: MIT · Data source: dwillis/congress-press
This data as json
| url | title | date | year | month | party | chamber | state | member_name | bioguide_id | domain | scraper | source | date_source | text | has_text | collected_at | updated_at |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| https://craig.house.gov/media/press-releases/representative-angie-craig-colleagues-urge-leader-schumer-bring-forward-stand | Representative Angie Craig, Colleagues Urge Leader Schumer to Bring Forward a Stand-Alone Vote on Capping Insulin Costs | 2022-09-06 | 2022 | 2022-09 | Democrat | House | MN | Angie Craig | C001119 | craig.house.gov | craig | https://craig.house.gov/media/press-releases | scraper | WASHINGTON, DC – Last week, U.S. Representative Angie Craig joined her colleagues in calling on Senate Majority Leader Chuck Schumer to hold a vote on her legislation capping the out-of-pocket cost of insulin at $35 a month for those with private insurance. Earlier this year, Representative Craig's Affordable Insulin Now Act, legislation that would cap the out-of-pocket cost of insulin at $35 per month, was passed out of the House. And while the provision of her bill capping the cost of insulin for those on Medicare was signed into law as part of the Inflation Reduction Act, the provision limiting the cost for those on private health insurance was stripped from the bill. "An estimated 14 percent of people with diabetes in the U.S. spend at least 40 percent of their income on insulin, causing catastrophic spending as insulin prices have more than doubled over the last 10 years," wrote the lawmakers. "We applaud the recent passage of the Inflation Reduction Act, which lowers costs for Americans with diabetes on Medicare by capping out-of-pocket insulin costs at $35 per month and is a historic step toward making insulin affordable for everyone." "It is imperative that we continue to advocate for a policy that caps out-of-pocket insulin costs for Americans on private health insurance who continue to pay exorbitant amounts for life-saving insulin. Therefore, we respectfully request that you hold another vote on the insulin cap in the Senate." they continued. Craig was joined in sending her letter by Representatives Raja Krishnamoorthi (IL-08), Dan Kildee (MI-05) and Lucy McBath (GA-06). You can read the full text of the letter and copied below. September 1, 2022 The Honorable Charles Schumer 322 Hart Senate Office Building Washington, D.C. 20510 Dear Senate Majority Leader Schumer, We write to urge you to advance legislation that eases the monthly cost of insulin for millions of Americans living with diabetes. Although we have made historic moves to cap out-of-pocket insulin costs for Medicare beneficiaries, Americans covered by private health insurance also deserve relief from the burden of excessive drug costs. Last month, you promised to bring insulin legislation to the floor again this fall and we stand ready to support you in those efforts. Over 37 million people in the U.S. have been diagnosed with diabetes and at least 1 out of 5 insulin users on private insurance currently pay more than $35 a month to obtain insulin.1 An estimated 14 percent of people with diabetes in the U.S. spend at least 40 percent of their income on insulin, causing catastrophic spending as insulin prices have more than doubled over the last 10 years. It should come as no surprise that for the vast majority of Americans, those prices are simply unsustainable. We applaud the recent passage of the Inflation Reduction Act, which lowers costs for Americans with diabetes on Medicare by capping out-of-pocket insulin costs at $35 per month and is a historic step toward making insulin affordable for everyone. It is imperative that we continue to advocate for policy that caps out-of-pocket insulin costs for Americans on private health insurance who continue to pay exorbitant amounts for life-saving insulin. Therefore, we respectfully request that you hold another vote on the insulin cap in the Senate. Capping out-of-pocket insulin costs at $35 per month is considered a top health care priority for Americans and at least 22 states have enacted state legislation capping insulin copayments.4 Despite the popularity of capping out-of-pocket insulin costs among voters, 43 Senators voted against affordable insulin for privately insured Americans during budget reconciliation. The House has demonstrated its commitment to lowering costs for American families struggling to afford insulin through its passage of the Affordable Insulin Now Act in March, and now the Senate must again consider legislation to assist the millions of Americans crushed by monthly drug costs. We thank you for your leadership on this issue and strongly urge you to advance this legislative priority in the Senate. Americans who depend on life-saving insulin everyday should not be forced to choose between buying groceries or buying insulin. We cannot wait another moment. ### | 1 | 2026-03-30T01:40:41Z | 2026-04-08T03:08:33Z |